Valadation of GR modulation in Prostate tumors | CORT Message Board Posts

Corcept Therapeutics Inc

  CORT website

CORT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  2733 of 2913  at  8/9/2019 1:52:02 PM  by

BSR_Alan


 In response to msg 2731 by  Pharmalong
view thread

Re: Valadation of GR modulation in Prostate tumors

Pharmalong,
 
I will affirm i760's comments. It's too early to tell. ORIC hasn't helped us. When the company does its public facing presentations and scientific articles, it compares its drug to Korlym (mfiepristone), not to any other Corcept drug.
 
That's no help.
 
I have consulted someone regarding the differences in the structure of relacorilant versus Oric's drug. There are some guesses but that's truly next to worthless.
 
Why?
 
The cows don't come home until we see the results. 
 
To Corcept's credit, they're testing three different drugs in prostate cancer: Korlym, Relacorilant, and CORT125281.
 
Believe it or not, if all things are equal, I'd like to see CORT125281 advanced to approval. It provides an additional "backup drug" to relacorilant and maybe even imparts additional flexibility around out-licensing. 
 
Of course, things are rarely equal. 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 205
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...